SeaCrest Wealth Management LLC Purchases New Position in Haleon plc (NYSE:HLN)

SeaCrest Wealth Management LLC acquired a new position in shares of Haleon plc (NYSE:HLN) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,696 shares of the company’s stock, valued at approximately $102,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of Haleon by 5.8% in the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares during the period. Clearbridge Investments LLC lifted its position in Haleon by 8.6% in the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock worth $344,888,000 after buying an additional 3,307,009 shares during the last quarter. Wellington Management Group LLP boosted its stake in Haleon by 49.9% during the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after buying an additional 3,046,841 shares during the period. Sculptor Capital LP increased its position in Haleon by 67.8% during the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after acquiring an additional 3,592,000 shares during the last quarter. Finally, Douglas Lane & Associates LLC raised its stake in shares of Haleon by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock valued at $82,274,000 after acquiring an additional 161,865 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Trading Up 0.5 %

NYSE HLN opened at $9.24 on Friday. The stock has a market cap of $41.80 billion, a PE ratio of 27.16, a PEG ratio of 2.52 and a beta of 0.29. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The company’s 50-day moving average price is $9.54 and its 200-day moving average price is $9.70. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Analyst Upgrades and Downgrades

HLN has been the subject of a number of recent analyst reports. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.